Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJG7M6)

• Drug Name: Azole benzene derivative 2 Drug Info
• Synonyms: PMID27841045-Compound-147
• Cross-matching ID:
  PubChem CID: 78322305
  TTD Drug ID: DMJG7M6

Molecule-Related Drug Atlas

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Gout	FA25	Approved	[2]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[3]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[4]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[6]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[7]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[8]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[9]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[10]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[1]

References

• [1] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
• [2] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [3] Clinical pipeline report, company report or official report of Takeda (2009).
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [5] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [6] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [7] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [8] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [9] Clinical pipeline report, company report or official report of Teijin Pharma.
• [10] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.